UK markets closed

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.7105+0.0105 (+1.50%)
As of 02:27PM EDT. Market open.
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
20,968
20,968
41,867
23,028
135,082
Cost of revenue
6,174
6,174
7,266
0
0
Gross profit
14,794
14,794
34,601
23,028
135,082
Operating expenses
Research development
108,510
108,510
91,879
82,701
107,851
Selling general and administrative
27,649
27,649
30,129
29,285
21,749
Total operating expenses
136,289
136,289
122,136
112,111
129,697
Operating income or loss
-121,495
-121,495
-87,535
-89,083
5,385
Interest expense
604
604
0
0
-
Total other income/expenses net
3,586
3,586
2,061
642
2,334
Income before tax
-118,513
-118,513
-85,474
-88,441
7,719
Income tax expense
-
-
0
0
-691
Income from continuing operations
-118,513
-118,513
-85,474
-88,441
8,410
Net income
-118,513
-118,513
-85,474
-88,441
8,410
Net income available to common shareholders
-118,513
-118,513
-85,474
-88,441
8,410
Basic EPS
-2.15
-2.19
-1.59
-1.74
0.18
Diluted EPS
-2.15
-2.19
-1.59
-1.74
0.18
Basic average shares
53,970
54,149
53,654
50,719
47,413
Diluted average shares
53,970
54,149
53,654
50,719
47,915